BioSpace News Archive

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies.

Major scientific breakthroughs are sometimes the result of a combination of serendipity and human error.

Pharvaris (Nasdaq: PHVS) today announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023, to be held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OTL-203, an investigational hematopoietic stem cell gene (HSC) therapy being developed for the potential treatment of the Hurler subtype of mucopolysaccharidosis type I (MPS-IH).

Algernon Pharmaceuticals Inc. is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast).

BioXcel Therapeutics, Inc. today announced that it will host a virtual Neuroscience R&D Day from 1:00 to 2:30 p.m. ET on Tuesday, Dec. 12, 2023.

Trevena, Inc. announced the acceptance of an abstract based on the pRospective, case-controlled Evaluation of oLIceridine for moderate or sEVEre pain in patients with acute burn injuries study at the 2024 ABA annual meeting, being held April 9th-12th in Chicago.

Nanoscope Therapeutics Inc. today announced that Jared Stephens , PhD, Vice President of Strategy and Business Development, will present at the 13th Annual Ophthalmology Innovation Summit (OIS) taking place from December 1-2 in San Diego, California.

Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology Research (IOR) today announced the commencement of a collaborative sponsored research agreement in prostate cancer.

Bicycle Therapeutics plc today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14.